🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

5 recruiting trials

for FGFR2 Gene Fusion/Rearrangement

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma NCT04353375Phase 2, Phase 31 site📍 Beijing Hutchmed · Tests: HMPL-453 A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement NCT06728410Phase 23 sites📍 Birmingham📍 Buffalo📍 Columbus Mehmet Akce · Tests: Pemigatinib, Durvalumab Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma NCT07786766Phase 21 site📍 Beijing Haitao Zhao, MD · Tests: Pemigatinb, PD-1 inhibitors, Chemotherapy Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement NCT05727176Phase 265 sites📍 La Jolla📍 Tampa📍 Detroit Taiho Oncology, Inc. · Tests: TAS-120
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy